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Diabetic Vitrectomy
Ogugua N. Okonkwo
Abstract
Diabetic retinopathy (DR) in its advanced stage is a leading cause of blindness 
and visual impairment. Despite efforts at early detection of DR, disease monitor-
ing, and medical therapy, significant proportions of people living with diabetes 
still progress to develop the advanced proliferative disease, which is characterized 
by neovascularization, actively proliferating fibrovascular membranes, and retinal 
traction. The surgical removal of this proliferating tissue and the treatment of the 
retinal ischemic drive can be very rewarding, providing significant stability of the 
retina and in several cases improved retinal anatomy and vision. Diabetic vitrec-
tomy comprises a broad range of surgical techniques and maneuvers, which offer 
the surgeon and patient opportunity to reverse deranged vitreoretinal anatomy and 
improve or stabilizes vision. Advances in vitreoretinal technology have contributed 
greatly to more recent improved outcomes; it is expected that future advances will 
offer even more benefit.
Keywords: diabetic retinopathy, vitreous hemorrhage, proliferative diabetic 
retinopathy, tractional retinal detachment, macular edema, vitrectomy
1. Introduction
Global estimates of diabetes have been on the rise [1]. Diabetic retinopathy 
(DR) is a leading cause of blindness among the working age group, with increasing 
numbers of persons being affected worldwide [2, 3]. It is a microvascular complica-
tion of diabetes which progresses to advanced disease in several cases. It is a global 
concern as indicated by a recent review published in Lancet [4]. The microvascular 
complications of diabetes result in macular leakage or exudation and vasoprolifera-
tive retinal disease, which are the hallmarks of advanced DR. Despite treatment of 
earlier stages of DR with medical therapy, which include intravitreal injection of 
anti-vascular endothelial growth factor (VEGF), intravitreal injection of steroids, 
and retinal laser photocoagulation, several eyes will progress to require surgical 
treatment [5–8].
Surgical treatment for the advanced complications of DR can range from more 
straightforward cases involving the removal of a non-clearing vitreous hemorrhage 
from an eye in which vitreous separation has already occurred, to more complicated 
surgical techniques such as in dealing with a combined tractional and rhegmatog-
enous retinal detachment (TRD/RRD) or tractional retinal detachment (TRD) 
involving the macula [9, 10]. The preoperative considerations, intraoperative 
techniques, and the postoperative outcome, including the complications of surgery, 
could vary considerably, depending on the risk factors and complexity of the 
vitreoretinal presentation associated with each case. Therefore surgical planning 
should be done on a case-by-case basis.
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Furthermore, in recent times, there have been significant improvements in 
preoperative care and evaluation, and intraoperative surgical technique, including 
the administration of preoperative intravitreal pharmacotherapy, development 
of small-gauge transconjunctival instrumentation [11–13], and availability of 
multifunctional vitrectomy probes with high cut rates [14]. These advances have 
made surgical outcome more predictable and have resulted in an expansion of the 
indication for vitrectomy in the management of the tractional complications seen 
in DR. This review will focus on highlighting the indications, pathophysiology and 
principles of surgery, preoperative considerations, intraoperative surgical tech-
niques, and outcome of diabetic vitrectomy in contemporary times.
2. Indications for surgery
The indications for vitrectomy in advanced DR have increased over the years 
from the situation in the early years of diabetic vitrectomy, when surgery was used 
for removing non-clearing vitreous hemorrhage. The first vitrectomy performed by 
Machemer was for the removal of non-clearing vitreous hemorrhage in a patient liv-
ing with diabetes, and suffering from proliferative diabetic retinopathy (PDR) [15]. 
The Diabetic Retinopathy Vitrectomy Study (DRVS) was the first randomized, large 
series study evaluating the outcome of early versus deferral of vitrectomy in eyes 
with vitreous hemorrhage secondary to advanced DR [16]. It highlighted the benefit 
of early vitrectomy especially in type 1 diabetics with more severe disease. The DRVS 
also demonstrated that the benefit of surgery was maintained over a 4-year study 
period. Since then, the indications for diabetic vitrectomy (DV) are now known to 
include non-clearing vitreous hemorrhage, TRD, combined RRD/TRD, vitreomacu-
lar traction, traction-induced diabetic macular edema (DME), rubeosis iridis, and 
macular distortion (including dragging of the macula), to mention a few [17–21].
1. Vitreous hemorrhage (VH): vitrectomy for vitreous hemorrhage removal, in sev-
eral studies, remains the most common indication for diabetic vitrectomy [20, 22, 
23]. The scope of this will depend on the surgeon’s personal experience, state of 
the fellow eye, previous retinal laser, recurrence of VH, and systemic control of 
glycemic levels. Non-clearing vitreous hemorrhage cases with complete separa-
tion of the posterior hyaloid are rather uncommon and the vitreous can be easily 
removed with expectation of improved vision in a majority of eyes. Vitrectomy 
for a case in which prior retinal laser photocoagulation has been applied also 
tends to progress quite well as the prior laser would have reduced the activity of 
the retinopathy, treated the retinal ischemia, and slowed the momentum of the 
disease. Moreover, in eyes with prior preoperative retinal laser, the occurrence of 
iatrogenic breaks within the areas of retinal laser scars prevents progression to 
retinal detachment. VH can at times be associated with more severe proliferative 
retinal disease such as a macula involving TRD. In this case both VH and TRD 
are indications for surgery and eventual visual outcome will be affected by the 
occurrence of TRD. This situation can be identified using a preoperative B scan 
ultrasound, which will reveal the TRD.
2. Retinal traction involving the macula can be an important indication for vitrec-
tomy. This can occur as a result of an epiretinal membrane (ERM), TRD, TRD/
RRD and vitreomacular traction (VMT). Fibrovascular proliferation (FVP) in the 
sub-hyaloid space is responsible for the retinal traction, which could initially oc-
cur in an extra macular site, and then progress to involve the macular area. Also, 
TRD could develop primarily in the macula and have an early impact on vision. 
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Surgery is indicated when the traction occurs in the macula or if there is obvious 
progression of an extra macular TRD towards the macula. In some cases the reti-
nal traction is significant and creates a retinal tear. This adds a rhegmatogenous 
component to the already existing TRD. In combined TRD/RRD, progression to 
involve the macula could be rapid, and early surgery is advised.
In these situations of significant traction involving the macula or threaten-
ing the macula, surgery is indicated to relieve the traction and reattach the 
retina or to prevent progression of TRD to the macula. However, there are sev-
eral cases in which extra macular TRD remains stable after adequate panretinal 
laser photocoagulation (PRP) and good control of systemic parameters have 
been achieved. Such cases can be observed since there is no progression.
In one review comparing African-Americans with Caucasians requiring 
diabetic vitrectomy, patients of African-American descent were found to be 
more likely to have TRD/RRD than Caucasians, and it was concluded that 
African-Americans might have a greater risk of developing this advanced com-
plication [24]. In the light of this, African-Americans and others at increased 
risk could benefit from earlier vitrectomy, before the onset of vision damaging 
advanced tractional complications.
3. Persistent retinal neovascularization despite adequate laser PRP may result 
in recurrent VH and requires surgical removal of the vitreous scaffolding on 
which such neovascularization would progress. In such cases, adequate retinal 
laser fails to cause a complete regression of neovascularization. The vascular 
tuft invades the vitreous scaffold and forms neovascular pegs. This vitreous 
attachment to the neovascular peg has to be removed to prevent the recur-
rent VH, which recurs whenever there is significant vitreous traction on the 
neovascular tuft.
4. Severe FVP, especially if associated with significant traction involving or 
threatening the macula, or if obscuring the macula, may require surgical 
removal. In some instances, FVP occurs in the retina periphery and may 
be associated with proliferation extending from sclerotomy sites. This was 
more common in the era of large sclerotomies using the 20-gauge vitrectomy 
systems. Residual postoperative peripheral vitreous and significant untreated 
ischemia in the peripheral retina using either endoretinal laser photocoagula-
tion or cryotherapy predispose to the formation of this complication better 
known as anterior hyaloidal fibrovascular proliferation (AHFVP) [25]. This is 
a known complication of diabetic vitrectomy which has also been reported to 
occur after cataract surgery in poorly controlled diabetic patients [25, 26].
Other indications for diabetic vitrectomy include macular ectopia and rubeotic 
glaucoma.
3. Preoperative systemic considerations
Diabetes is a multisystem disease. The presence of DR suggests microvascular 
affectation, which may include an effect on the microvasculature in other organs, 
especially the kidney resulting in diabetic nephropathy. Advanced retinopathy 
requiring surgery has been found to be associated with reduced life expectancy 
[27]. Also patients with diabetic macular edema have been noted to have a higher 
incidence of cerebrovascular accidents and myocardial infarcts [28].
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As the patient for diabetic vitrectomy could be ill before or after the surgery, 
careful review by the internist and anesthesia team is required before the decision 
to proceed to surgery is taken. If the patient is on routine dialysis, heparin-free 
dialysis may be beneficial in reducing the incidence of intraoperative and postop-
erative hemorrhage. Preoperative administration of intravitreal VEGF injection has 
become popular in recent times and has been shown to decrease the rate of intraop-
erative and postoperative hemorrhage; it also improves intraoperative visibility and 
reduces surgery time.
Importantly, an internist clearance is required before preoperative adjunctive 
anti-VEGF is administered to avoid a situation in which following the administra-
tion of anti-VEGF, surgery is postponed due to the patient’s ill health. This may 
result in an overactivity of the anti-VEGF with severe contraction of the fibrous 
component of the fibrovascular membrane resulting in a worsening TRD (and 
perhaps more retinal ischemia); this is known as a “Crunch.” The use of anti-VEGF 
will be discussed in more detail later on.
4. Preoperative ocular considerations
1. Visual acuity: preoperative acuity has been shown to be an important factor 
in determining the eventual postoperative visual outcome, with eyes having 
better preoperative vision tending to have improved postoperative vision. Also, 
TRD involving the macula will have poorer preoperative vision than a “macu-
lar sparing” TRD. Therefore surgery should be performed once the macula is 
perceived to be threatened. Macular ischemia remains an important reason for 
poor preoperative and postoperative vision; this can be determined by the use 
of fundus fluorescein angiography (FFA) to assess for macular non-perfusion. 
Optical coherence angiography (OCT angiography or OCTA) can also be used 
and has the advantage of repeatability of the test. However, in several cases, it 
is not possible to perform this FFA assessment of the macular vasculature be-
fore surgery because of opacities in the medium, including VH and FVP, which 
obscure the view of the macula.
2. Intraocular pressure (IOP): this may be normal or elevated. When IOP is el-
evated, it is important to assess the anterior chamber angles and anterior uvea 
carefully, in search of rubeosis. The finding of rubeosis suggests very signifi-
cant retinal ischemia and further worsens the prognosis for recovery of vision. 
The rise in IOP may also have damaging effects on the cornea, including cornea 
edema, and result in decreased visibility during surgery.
3. Cornea: the clarity of this structure is required for proper access and visibil-
ity required for diabetic vitrectomy. The use of contact lens viewing systems 
significantly increases the incidence of cornea opacity and may require the 
removal of cornea epithelium during the surgery. Such scrapping off of cornea 
epithelium could result in postoperative cornea defects, which could take some 
time to heal. The aforementioned situation has been greatly reduced with the 
more frequent use of non-contact lens viewing systems.
4. Pupil: it is vital to assess for adequate pupillary dilatation prior to surgery. A 
poorly dilating pupil may require more than pharmacological mydriasis. In 
some instances pupillary synechiae may exist and will require mechanical dila-
tation such as using iris hooks.
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5. Lens: the presence of significant cataract may require that a combined vitrec-
tomy and cataract removal be performed during the same surgery. The cata-
ract is first removed using a phacoemulsification technique, then the diabetic 
vitrectomy is performed. The intraocular lens (IOL) could be inserted before 
or at the conclusion of the vitrectomy. This combined procedure has become a 
popular technique in recent years. It provides a clearer view and lends itself to 
improved access to the retina periphery with the use of a wide-angle viewing 
lens. However, it can also be associated with significant complications of the 
anterior segment, since there could be enhanced diffusion of the growth fac-
tors including VEGF from the posterior segment to the anterior segment of the 
eye, resulting in the formation of rubeosis iridis and its sequelae.
6. A B scan ultrasound is a useful ocular investigation to have, especially in situ-
ations in which there is limited or no view of the retina as a result of vitreous 
hemorrhage, opacities in the vitreous, and cataract. A B scan can detect the 
presence or absence of posterior vitreous detachment (PVD) and provide 
information useful for preparing the eye for diabetic vitrectomy. For instance, 
some surgeons would give preoperative intravitreal anti-VEGF in eyes without 
a PVD and refrain from doing so in eyes in which a PVD already exists. Also a B 
scan can detect the presence of vitreoschisis (aka second membrane). Vitreos-
chisis is common in diabetic retinopathy eyes, and for this reason re-staining 
using multiple intravitreal triamcinolone injections is important to detect the 
residual vitreous layer when vitreoschisis is present. Vitreoschisis is thought to 
be due to vitreous hemorrhage in the gel splitting the vitreous fibers. Recogniz-
ing its presence is essential for good outcome.
5. Relevant pathophysiology and surgical principles
Advanced stages of DR are characterized by retina edema and ischemia, 
consequent to vascular hyperpermeability and vascular occlusion, respectively. 
The chronic hyperglycemia results in progressive damage to the retinal capillary 
network resulting in retinal hypoxia and release of hypoxia-inducible factor (HIF) 
from the affected areas of the retina. The resultant ischemic retina due to the action 
of HIF then releases pro angiogenesis growth factors which include basic fibroblast 
growth factor (FGF), insulinlike growth factor 1 (IGF 1), erythropoietin, and, 
the most known growth factor, VEGF [29]. Also, cytokines such as IL-6, IL-8, and 
MCP-1 are released. The interaction of these growth factors and cytokines stimulate 
angiogenesis. VEGF-mediated new blood vessels sprout out from the surrounding 
vessels, i.e., capillaries and venules, and invade the vitreous. Progressive vasop-
roliferation occurs in response to increasing levels of the growth factors; and this 
is associated with proliferation of fibrous tissue resulting in the characteristic 
fibrovascular membranes. The fibrovascular tissue proliferates and extends across 
the retina in the preretinal space (or sub hyaloid space). In eyes with PVD, fibro-
vascular membranes can only grow on the surface of the retina; therefore, retinal 
detachments do not tend to occur. However in eyes without a PVD (which is often 
the case), the posterior hyaloid acts as a scaffold that allows the fibrovascular tissue 
to grow, leading to traction on the retina and retinal detachments. Tractional forces 
within the vitreous exert effect on these rather brittle new blood vessels resulting 
in different degrees of hemorrhage. The resulting hemorrhage can range from a 
small leakage of blood on the surrounding retina to larger preretinal hemorrhage 
(Figure 1a) and to a more severe break through intragel vitreous hemorrhage. 
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This hemorrhage can often be removed using vitrectomy technique (Figure 1b). 
The fibrous component of the fibrovascular tissue contracts, due to a myofibro-
blastic effect [30], and causes traction on the inner retina, resulting in a TRD that 
may initially involve an extra macular site, and then subsequently progresses to the 
macula and damages vision. In some cases the traction results in a split in the layers 
of the retina (retinoschisis or foveoschisis) that can be appreciated on optical coher-
ence tomography (OCT) scan. Similarly, ERM may be present in the macular area 
and result in considerable macular traction, worsening already existing macular 
edema. Since such diabetic macular edema (DME) has a traction-induced compo-
nent as its causation, surgery will be required to remove the traction if resolution of 
the edema is to be achieved. VEGF suppression alone is unlikely to achieve complete 
resolution of this sort of DME, and this needs to be recognized.
The surgical principles of diabetic vitrectomy include performing a core vitrec-
tomy. In some cases, a posterior vitreous separation already exists preoperatively 
and the goal of surgery is simply vitreous hemorrhage removal. This is a rather 
uncommon presentation. In cases of vitreous hemorrhage removal, in addition 
to the hemorrhage (since the vitreous cavity acts as a reservoir of several pro-
inflammatory and pro-angiogenic factors that result in macular edema, neovascu-
larization, and proliferation of fibrous tissue), diabetic vitrectomy also achieves 
immediate removal of these factors and cytokines. It facilitates access to the retina 
and permits release of the posterior hyaloid and further dissection of the tractional 
fibrotic membranes that create the TRD.
Separation of the anterior vitreous from the more posterior cortical vitreous can 
be easily accomplished using any standard vitreous cutter, allowing the release of the 
anteroposterior traction induced by the vitreous. Careful dissection of the posterior 
vitreous cortex from the underlying retina and the removal of proliferating fibro-
vascular membranes and fibrous bands from the retina surface (and at times from 
the subretinal space) are the highlights of the surgery. This should be done, avoiding 
the creation of iatrogenic breaks and creation of false passages. Identification of the 
right plane of vitreoretinal separation is the key to proper dissection and avoiding 
unnecessary iatrogenic breaks. One tip to achieve entry into the right vitreoretinal 
plane in difficult situations is to commence dissection from the optic disc and then 
move out towards the macula and retina periphery, the “inside out approach.” In 
Figure 1. 
Fundus photograph of PDR. (a) Left eye showing diffuse vitreous hemorrhage and preretinal hemorrhage in 
an eye diagnosed to have PDR. Notice also the absence of retinal laser marks and presence of macula hard 
exudates, with some significant cataract. (b) Same eye as in 1a after vitrectomy; view of the fundus is clearer 
and some hard exudates persist in the macular area.
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practice, it is possible to detach the vitreous at the optic disc with gentle traction on 
the adjoining vitreous or fibrous tissue close to the optic disc using an intraocular 
forceps or the aspiration port of a vitreous cutter. This lifts the vitreous off the disc 
and ensures a safe entry into the vitreoretinal space, from where dissection can 
continue outward. In some cases a moderate to large amount of retrohyaloid blood 
already exists; this provides a useful entry point into the desired vitreoretinal space.
Techniques for fibrovascular proliferation removal have been well described 
and include en bloc dissection in which vitreous and proliferating tissue is removed 
as one, segmentation of fibrovascular tissue into islands of tissue using straight 
scissors or small-gauge cutter, and delamination involving careful removal of the 
islands of tissue using a small-gauge cutter or a curved intraocular scissors [31, 32]. 
Various ancillary instrumentation including picks, vertical and horizontal scissors, 
blades, membrane peeler cutters, forceps, scrapers, and other instruments can be 
used for the removal of proliferating fibrovascular membranes. However the use 
of newer high cut rate multifunctional vitreous cutters enables surgeons to often 
complete TRD repair using only the vitreous cutter [33, 34].
Upon completion of membrane dissection, ERM in the macular area may require 
identification and removal. Subretinal fluid drainage may be required. Existing 
retinal ischemia is treated with the application of laser panretinal photocoagula-
tion [35]. PRP should be done up to the extreme retinal periphery, i.e., ora serrata. 
Scleral indentation is performed in search of iatrogenic retina breaks (which if 
undetected and treated can result in postoperative RRD and need for re-vitrec-
tomy). Indentation is also done to ensure PRP has been extended to all areas of 
peripheral ischemia. Some surgeon will apply cryotherapy to the peripheral retina, 
to ensure maximum obliteration of the ischemic drive.
There may be a need for longer acting tamponade such as silicone oil in the more 
complex retina detachments such as in TRD cases with the occurrence of significant 
iatrogenic breaks, TRD/RRD situation, or in cases with existing traction [36]. 
Silicone oil is also used in monocular patients and patients who cannot position or 
who have to undertake air travel soon. Otherwise air, saline or shorter acting tam-
ponade such as SF6 is sufficient in cases of low to medium complexity, especially if 
there are no iatrogenic breaks and release of traction is considered adequate. C3F8 
can be used if longer duration of tamponade is required. It is important to ensure 
that sclerotomy ports are well closed, with no leakage. If required and judged to 
be necessary, sclerotomy sites should be sutured using, e.g., 8-0 vicryl suture, to 
prevent hypotony and reduce the risk of postoperative vitreous hemorrhage. A 
reported disadvantage of the sutured sclerotomy is postoperative patient discomfort 
and induction of cornea astigmatism, which tends to settle and return to preopera-
tive status over some weeks.
6. Intraoperative considerations
Diabetic vitrectomy has benefited from the overwhelming advances that have 
occurred in vitrectomy over the past decade. This includes advances in surgical 
technique, instrumentation, improved preoperative patient work-up, and case 
selection. All this has resulted in improved surgical outcome, which has further 
increased surgeon confidence in performing surgery, even in the more complex 
vitreoretinal cases. Some of these advances in diabetic vitrectomy and their impact 
are as enumerated and discussed below:
1. Improvements in vitrectomy machines and probes, which includes faster cutting 
rates and smaller gauges (27 G, 25 G, and 23 G) trans conjunctival vitrectomy 
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systems, now means that these probes can be used as multifunctional tools. 
They can be inserted carefully beneath tractional membranes during surgery 
and used effectively for segmentation and delamination of the membranes 
without the need for intraocular scissors in several cases. Also the high cut rates 
provide for less traction on the retina, reduce the mobility of the retina, and 
reduce the rate of iatrogenic breaks. The presence of the vitrectomy cutting port 
closer to the tip of the probes means that membranes on the retina can be easily 
engaged. Indeed many complex cases can be safely completed with the use of 
only the vitreous cutter and no other ancillary instruments required. Similarly 
the protection conferred by the cannula system at the sclerotomy entry site pro-
vides for reduced incidence of entry sight breaks, vitreous incarceration at the 
wound edge, and leaking sclerotomies.
2. The introduction of intraoperative self-retaining lighting systems, such as 
the chandelier illuminating system, provides a free hand which can be used 
to grasp and stabilize intraocular tissue with a forceps while a fibrovascular 
membrane (FVM) is being dissected away. This led to the use of bimanual sur-
gical technique. Bimanual surgery provides a very useful means of membrane 
dissection in difficult TRD and TRD/RRD cases, with broad attachment of 
fibrovascular membrane to the retina. Also various illuminated instruments, 
such as the lighted peaks, can provide considerable support in membrane dis-
section and relief of traction.
3. During the early days of diabetic vitrectomy, as the era of the DRVS, the 
ability to perform endoretinal photocoagulation was lacking. The presence 
of endoretinal photocoagulation probes has provided additional stabiliza-
tion to the surgery outcome, since panretinal laser photocoagulation can now 
be done during the surgery irrespective of the occurrence of postoperative 
vitreous cavity hemorrhage. Supplemental retinal laser photocoagulation may 
be required in addition to already existing retinal laser marks. PRP should be 
adequate and done up to the retina periphery to cover the ischemic retina and 
prevent postoperative complications such as recurrent hemorrhage or AHFVP.
4. The intraoperative use of triamcinolone crystals to highlight the posterior 
vitreous cortex has helped visualization and improves complete removal of the 
vitreous. In some cases vitreoschisis is present, and this can be detected if the 
additional triamcinolone is used. Also vital dyes such as brilliant blue G (BBG) 
and membrane blue (MB) have been found to help in highlighting ERM and 
ILM, therefore facilitating its removal. While the removal of ILM is justified 
in the macula to prevent re-proliferation of membranes, in some cases this can 
be quiet difficult, especially in the presence of significant macular edema, with 
pathologically adherent ILM. In such cases with a risk of further trauma to the 
macula, ILM peel is best avoided. Injection of PFCL, which acts to stabilize the 
retina during the ILM peel, in some cases, may improve the chances of success-
ful ILM peel.
5. Obtaining a preoperative OCT has become a standard work-up procedure 
for eyes with diabetic retinopathy (Figure 2a). Aside from providing use-
ful histological overview of the retina and vitreous, it can be used to provide 
three-dimensional overlay including showing areas of vitreoretinal adhesion, 
pegs as they are called, and areas of vitreous separation, which is important 
for surgical planning. Also it provides additional information on prognosis for 
postoperative vision, since eyes with more preoperative preserved external 
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limiting membrane (ELM) and ellipsoid zone (EZ) layers (as in Figure 2a) 
have been demonstrated to have better postoperative vision than eyes without, 
since a preserved EZ and ELM are also expected after surgery (Figure 2b). The 
postoperative presence of EZ and ELM, which are outer retinal layers, are es-
sential predictors of postoperative recovery of vision.
Fairly decent OCT images can be obtained in eyes with a limited amount of 
vitreous hemorrhage as in Figure 2a. Unfortunately in some of the eyes with 
an obscured view of the retina, OCT is not possible. However, the successful 
incorporation of OCT technology into the operating microscope provides the 
intraoperative OCT (iOCT), which has shown usefulness in intraoperative 
Figure 2. 
OCT images of same patient whose fundus picture is shown above. (a) Preoperative crossline OCT images of 
the same eye as in Figure 1a. Notice the presence of localized macular edema and vitreous hemorrhage with 
PVD. (b) Postoperative OCT images with normal subfoveal thickness but some intraretinal cystic spaces.
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decision-making. The iOCT can help in determining the intraoperative pres-
ence of unremoved traction inducing ERM in the macula or the occurrence of 
a macular hole, which requires to be addressed during the surgery, since this 
can significantly affect postoperative visual outcome.
6. Timing of surgery: there is considerable interest in improving the visual 
outcome of eyes undergoing diabetic vitrectomy. This has resulted in some 
advocacy for earlier surgery in the category of patients with proliferative 
disease, instead of waiting for progression to more advanced TRD. Also efforts 
at inducing a pharmacologic separation of the vitreous from the retina using 
enzymatic vitreolysis have not been rewarding. Much of diabetic vitrectomy 
has to do with the separation of the attached vitreous. Induction of posterior 
vitreous separation could significantly halt the progression of PDR, since the 
attached vitreous is required for continued FVP.
On the other hand, there are advocates for caution in diabetic vitrectomy, 
who argue for the more aggressive use of a combination of intravitreal 
anti-VEGF and retinal laser photocoagulation. They argue that the outcome 
of diabetic vitrectomy could be unpredictable and that even in seemingly 
straightforward cases, intra- and postoperative complications was not uncom-
mon. Diabetic vitrectomy according to them should be undertaken only when 
necessary and other medical options exhausted.
7. Pharmacologic adjuvants: In recent times the use of pharmacological therapy 
has been introduced as adjuvant for use preoperatively and intraoperatively in 
diabetic vitrectomy. Intravitreal Injection of anti-VEGFs including Macugen, 
Avastin, and Lucentis has been used preoperatively and postoperatively, while 
steroid implants such as Ozurdex have been used pre- and intraoperatively.
Bevacizumab (Avastin, Genentech, South San Francisco, CA, USA) appears 
to be the most commonly used preoperative anti-VEGF injection [37, 38]. 
Preoperative injection of anti-VEGF agents is known to considerably shrink 
neovascular fronds and has been shown to reduce intraoperative and postop-
erative bleeding and result in improved visual outcome [38–42]. However, an 
overaction of anti-VEGF can cause contraction of fibrovascular membrane 
and could exacerbate the traction and cause progression of TRD, in some cases 
causing a macular sparing TRD to involve the macula. This has been called the 
“crunch syndrome” which is characterized by a worsening tractional retinal 
detachment and development of denser fibrotic connections between the 
retina and overlying tissue, which makes it harder to identify tissue planes and 
results in more difficult dissection of the fibrous membranes [43].
Therefore the optimum time for anti-VEGF injection preoperatively should 
be enough time to cause the desired effect, which is reduction in neovascular-
ization, and not long enough to induce severe fibrotic contraction and wors-
ening of TRD. It is generally thought that the ideal time frame is somewhere 
between 3 and 5 days prior to surgery, with considerable variation among 
surgeons. This time frame enables neovascular regression while limiting 
fibrovascular membrane contraction.
Pegaptanib (Macugen, Bausch, and Lomb, Bridgewater, NJ, USA) has been 
used as an adjunct, when injected preoperatively. Pegaptanib is a PEGylated 
aptamer and only inhibits the VEGF isoform 165 [44]. It therefore has been sug-
gested to have a more selective effect on the neovascularization component of the 
fibrovascular membrane and less tractional effect with lower systemic risks [44]. 
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Therefore it can be used to induce regression of neovascularization, in a way 
similar to bevacizumab, and therefore reduces the risk of intraoperative bleeding, 
but does not have a similar tractional effect as seen with the use of bevacizumab 
[45]. This may allow for injection of Pegaptanib at any given time prior to sur-
gery, even in the form of multiple injections, awaiting physician clearance, and 
good timing for surgery. There is however no wide spread use of Pegaptanib for 
this purpose, and comparison with bevacizumab has not been done. It may also 
be systemically advantageous due to the lower risk of vascular accidents in these 
high-risk patients [44]. It is instructive to mention that Pegaptanib is rarely used 
as an anti-VEGF of choice for suppression of VEGF in other neovascular ocular 
pathologies.
Ozurdex (Allergan, Dublin, Ireland) is a biodegradable 0.7 mg dexametha-
sone implant that is injected intravitreally via a 22-gauge needle and has been 
approved by the Food and Drug Administration (FDA) for the treatment of 
DME. It has been used in the pre- and postoperative control of the neovas-
cularization process and tissue edema. As noted by Mahmoud et al., it can be 
injected preoperatively in an eye with extensive TRD in which it facilitates 
regression and consolidation of neovascularization in addition to inhibiting 
other inflammatory cytokines [45]. Unlike anti-VEGF agents, it is not known 
to increase risk of systemic complications, and there is no associated fibrovas-
cular membrane or retinal tractional response. Tissue planes were found to 
be more distinct and not changed into flat fibrovascular tissue, making them 
more difficult to dissect, as was seen following administration of anti-VEGF 
agents. Due to these properties, it provides for flexibility with operative physi-
cian clearance planning (there is adequate time for preoperative clearance 
when Ozurdex is being used). In addition, the effect of Ozurdex can continue 
well into the postoperative period, since the Ozurdex implant can remain in 
position in the postoperative period under silicone oil [45]. Ozurdex implant 
releases the active drug over a period of 6 months and therefore keeps the eyes 
quiet, and the neovascular process is inactive during the postoperative period.
8. Techniques and tips for fibrovascular membrane dissection. Certain tech-
niques are useful in the safe removal of fibrovascular tissue. The following are 
by no means exhaustive and are at best suggestions:
a. Smaller-gauge (25 G and 27 G) transconjunctival surgery can provide 
opportunity for the vitrectomy probe to be inserted between the mem-
brane and the retina. Using an aspiration mode, the membrane is lifted up 
with the cutting edge of the probe facing superiorly. As soon as resistance 
to the membrane lifting is encountered, the membrane is cut with the cut-
ter. In this way the fibrovascular membrane is segmented; then the islands 
of fibrovascular tissue are removed from the retina using a delamination 
technique. Using the probe in this fashion, it can also serve as a blunt 
dissector and can be used without the need for additional instrumentation 
such as scissors or pick.
b. Viscodissection is a very useful technique in cases of very adherent mem-
branes [46, 47]. It was born from the idea that the use of liquid or fluid 
instead of metal or other materials to separate membranes from normal 
retina would have safety advantages. The use of small tip retractable 
cannulas, which can be inserted into small spaces between fibrovascular 
membranes and detached or attached retina, enables injection of hyalu-
ronic acid (HA). The HA serves to separate the membrane from the retina, 
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and the viscodissection cannula can be used for blunt dissection as well. In 
addition, the HA provides hemostasis and improves visibility in the area of 
the dissection. Care should be taken to ensure adequate removal of the HA 
after the surgery to prevent a rise in IOP.
c. In the extremely difficult cases of TRD and TRD/RRD, characterized by 
thickened fibrotic membranes strongly adherent to the retina, a combina-
tion of forceps with curved scissors is a good option. With the use of a 
bimanual technique using a chandelier illumination placed at 12 O clock 
position (or any other position as chosen by the surgeon) and wide-angle 
viewing, the edge of thickened fibrovascular membranes can be engaged 
using a good gripping tissue forceps and then separated from the retina 
with scissors. After the separation, the membrane or clot can then be cut 
off with the small-gauge cutter using reduced cut rates.
d. Proportional reflux is a feature of the Constellation vitrectomy machine 
and other machines that have been used in the safe dissection of mem-
branes from the normal retina [48]. The Constellation Vision System 
(Alcon Laboratories, Fort Worth, TX) has the pulse reflux mode, which 
allows a jet of fluid to be ejected from the port and is useful for ejecting 
accidentally incarcerated tissue during vitrectomy. In addition to this, it 
also has a proportional reflux mode. The proportional reflux mode allows 
for fluid to be ejected from the vitrectomy probe port in a gradual and con-
trolled manner with foot pedal control, thus the term proportional reflux. 
The concurrent development of microincisional vitrectomy surgery with 
a smaller gauge and the port being closer to the tip as well as the develop-
ment of proportional reflux has allowed for a new surgical technique 
known as “proportional reflux hydrodissection” [48, 49]. In this technique, 
credited to Dugel, the port of the cutter is placed between the fibrovascular 
tissue and the normal retinal tissue. Thereafter, with the foot pedal, the 
surgeon has complete control over fluid extrusion in a proportional fashion 
to create a separation between the fibrous tissue and the normal retina.
7. Complications of surgery
Vitrectomy in an eye that suffers from PDR can have significant complications. 
This ought to be considered and the risk for these intra- and postoperative compli-
cation considered before the decision to perform surgery is taken. Some of these 
complications include intra- and postoperative vitreous cavity hemorrhage (early or 
delayed), recurrent vitreous hemorrhage, hypotony, progression of diabetic reti-
nopathy, iatrogenic retinal breaks (commonly occurring during fibrovascular tissue 
dissection), cornea edema, sclerotomy-related complications including vitreous 
incarceration (not as common with small-gauge vitrectomy compared to 20 G era), 
vascular ingrowths and AHFVP, rapid progression of cataract, phototoxicity (asso-
ciated with chandelier illumination placement close to the retina), rubeosis and 
rubeotic glaucoma (more common in pseudophakia and aphakia), and severe loss 
of vision. Rubeotic glaucoma is a troublesome disease to manage and will require 
the use of intravitreal anti-VEGF, retinal laser photocoagulation, or cryotherapy. 
In some cases additional cyclodestructive procedure or glaucoma drainage tube 
surgery may be indicated. Fortunately the incidence of this complication is on the 
decline due to the use of laser endo photocoagulation, which enables more aggres-
sive management of the peripheral ischemia.
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Much of the complications can be avoided with meticulous attention to currently 
available surgical techniques. For instance, the rate of intra- and postoperative 
hemorrhage can be reduced by the use of preoperative intravitreal anti-VEGF as 
previously described and careful hemostasis during surgery either by the elevation 
of intraocular pressure, cautious diathermy, direct application of pressure to bleed-
ing vessels, or application of viscoelastic to the point of bleeding. Also preoperative 
discontinuation of blood thinners and attention to the systemic blood pressure 
during and after surgery to ensure it is not elevated can be helpful.
8. Outcome
In recent times due to improvements witnessed in vitrectomy technology and 
technique as previously discussed, the anatomical and visual outcome of diabetic 
vitrectomy has generally improved. Compared to the earlier era, when endoretinal 
laser photocoagulation for treating retinal ischemia intraoperatively was not avail-
able (retinal ischemia is the main drive for the proliferative retinal changes), we 
now have a host of retinal laser photocoagulation probes available for use during 
vitrectomy. There have been reports of improvements in visual acuity in 75% and 
87% of TRD eyes and vitreous hemorrhage eyes, respectively [50, 51]. With contin-
ued improvements and probably earlier timing of surgery, success rates will likely 
continue to improve and may exceed the 90% rates. Some of the poor prognostic 
factors include poor pre-op visual acuity, rubeosis, ectopia or displacement, and 
macula involving TRD. Significant fovea ischemia, which can be recognized with 
the use of fundus fluorescein angiography and OCTA, has a poor prognosis.
To conclude, diabetic vitrectomy has benefited from the advances in the sphere 
of vitreoretinal surgery. Though presentation of proliferative DR is very variable 
and can be complex, modern tools and technique can in most cases improve or 
stabilize vision. There is an ongoing discussion on possible identification of eyes at 
risk for progression and offering earlier surgery. This may result in further improve-
ments. Perhaps the development of an ideal pharmacologic vitreolytic agent which 
will induce a PVD in eyes known to have PDR will usher in a new era in diabetic 
vitrectomy.
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